SciTech Development Inc, a clinical-stage oncology company advancing ST-001 nanoFenretinide, said on Wednesday that early-stage clinical data from its ongoing Phase 1a trial will be presented at the USCLC Annual Workshop 2026 in Denver, Colorado on 26 March 2026.

Principal investigator Auris Huen, MD, PharmD, associate professor of Dermatology at The University of Texas MD Anderson Cancer Center, will present 'Clinical Benefit, High Systemic Exposure, and Manageable Toxicity in a First-in-Human Trial of ST-001 nanoFenretinide in Previously Treated Cutaneous T-Cell Lymphoma', which will highlight emerging data from SciTech's clinical trial evaluating ST-001 in patients with Cutaneous T-Cell Lymphoma (CTCL), a subtype of T-cell non-Hodgkin lymphoma.

The presentation will feature early clinical findings demonstrating meaningful anti-tumour activity, including complete and partial responses, alongside a favourable safety and tolerability profile. The data also underscores the ability of ST-001's proprietary nanoparticle delivery platform to achieve enhanced systemic exposure -- addressing a longstanding bioavailability limitation of fenretinide and supporting its therapeutic potential, SciTech said.

The Phase 1a trial is fully enrolled and nearing completion, with data supporting the advancement of ST-001 into the next phase of clinical development.